ImmunityBio Inc
ImmunityBio, Inc. is a biotechnology company focused on developing immunotherapies for the treatment of cancer and other serious diseases.
Price history of ImmunityBio Inc
Price history of ImmunityBio Inc
Performance & Momentum
ImmunityBio Wins First Approval in Asia
ImmunityBio said its ANKTIVA treatment has received regulatory approval in Macau for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer. This is the drug's first approval in Asia, further validating its commercial potential beyond the United States and paving the way for a gradual international expansion. The news is positive for IBRX, as it strengthens visibility on future ANKTIVA sales and lends credibility to the company's global development strategy. Meanwhile, the recent progress in regulatory approvals and bullish analyst calls is supporting market sentiment, even though the company remains exposed to regulatory and commercial execution risks.
Strategic Analysis
ImmunityBio Inc • 2026
ImmunityBio positions itself as a biotech company specializing in immunotherapies targeting cancer and other serious diseases, with an approach focused on turning clinical results into marketable treatments. Its investment appeal is based on a pipeline-and-regulatory-execution logic, where each approval can strengthen the platform's credibility and open new growth drivers. The first approval obtained in Asia confirms that the company is reaching a stage of monetization and international validation.
- Exposure to a high-value segment, with significant value-creation potential if the clinical portfolio continues to materialize
- Recent regulatory validation in Asia, which improves commercial visibility and lends credibility to the platform
- Very strong stock momentum, reflecting renewed market interest in the growth and execution story
- Heavy dependence on regulatory decisions and clinical success, with an inherently volatile profile
- Still uneven long-term stock-market track record, highlighting the risk of dilution or execution disappointment
Momentum is very strong and reflects a clearly bullish trend, supported by a re-rating of the stock around regulatory progress. The approval in Asia acts as a positive catalyst, reinforcing the perception of a gradual transition from scientific potential to real commercial execution. For investors, this suggests a stock that has regained medium-term appeal, but remains sensitive to clinical and regulatory announcements.
Similar stocks to ImmunityBio Inc
Recent News
ImmunityBio Inc
Judicial Probe Launched Against ImmunityBio (IBRX)
2 months agoOn February 17, 2026, law firm Pomerantz LLP announced an investigation into claims filed by ImmunityBio investors, urging affected parties to come forward. This legal notice emerges amid shaken investor confidence, reflected by a notable downward trend in the stock, despite an intriguing but likely volatile 4.7% price surge.
ImmunityBio's Anktiva Revenues Soar 700%, Saudi Approval
4 months agoImmunityBio (NASDAQ: IBRX) reported a remarkable 700% increase in Anktiva-related revenues, reaching $113 million in 2025, driven by promising geographic expansion. Additionally, the company secured regulatory approval from the Saudi Drug Authority for a bladder cancer treatment, strengthening its commercial position. These developments, along with positive clinical outcomes highlighted by analysts, provide renewed momentum for ImmunityBio, likely to boost short-term investor interest.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
